|Printable version||E-mail this to a friend|
Zika virus infection: plasma- and urine-derived medicines safe to use
Manufacturing processes for these products successfully inactivate or remove virus.
Assessments carried out by the European Medicines Agency (EMA) and competent authorities in the EU Member States have confirmed that there is no increased risk of contamination with the Zika virus for patients who take plasma-derived or urine-derived medicines.
Plasma-derived medicines are manufactured from human blood. They are used to treat and prevent serious diseases and include coagulation factors (treatments which help blood to clot) and immunoglobulins (proteins used in patients who need more antibodies in their blood to help fight infections and other diseases). Urine-derived products are manufactured from pooled human urine and include certain hormone-based treatments and urokinase products (medicines used to break up blood clots).
These medicines are produced from body fluids, which might be sourced in parts of the world where the Zika virus is prevalent. EU regulators sought reassurance that there is no risk of the virus contaminating the final product and thus affecting the patients taking it if the plasma or urine came from donors who had contracted the Zika virus.
EMA’s Committee for Medicinal Products for Human Use (CHMP) has addressed the potential risk from Zika virus for plasma-derived medicinal products. The CMDh has coordinated the assessment by EU Member States on the potential risk from Zika virus for urine-derived medicinal products.
The CHMP concluded at its meeting last week that the manufacturing processes used for plasma-derived products, including for example the solvent/detergent method to inactivate viruses, pasteurisation (liquid heat inactivation) and virus filtration, inactivate or remove the Zika virus from the finished product. The CHMP therefore considered that no additional safety measures such as the testing or exclusion of certain plasma donors was necessary.
Concerning urine-derived products, the CMDh, following the assessment of the data, concluded that the manufacturing processes for these products contain complementary steps with inactivation/removal capacity for enveloped viruses, which are considered sufficient for Zika virus safety of these products. Additional safety measures such as the screening of urine donors or donations or the deferral of donors returning from affected areas are not considered necessary.
The findings from these assessments on the viral safety of plasma-derived and urine-derived medicines are available in a report from the CHMP’s Biologics Working Party(BWP) published yesterday.
- The CMDh is a medicines regulatory body representing the European Union (EU) Member States.
- The Biologics Working Party (BWP) provides recommendations to EMA’s scientific committees on all matters relating directly or indirectly to quality and safety aspects relating to biological and biotechnological medicines.
- The BWP recommendation on plasma-derived products is in line with the guidance published in July 2016 by the European Centre for Disease Prevention and Control (ECDC) entitled “Zika virus and safety of substances of human origin - A guide for preparedness activities in Europe”.
|Zika virus infection: plasma- and urine-derived medicines safe to use||(English only)||21/09/2016|
Latest News from
Car rental companies improve treatment of consumers, thanks to EU-wide enforcement20/01/2017 16:25:00
Following a strong increase of the number of complaints on car rental issues, the European Commission and national consumer authorities engaged with the five leading car rental companies to address these issues.
Human rights: Indonesia, Central African Republic and Burundi20/01/2017 15:25:00
Parliament condemns growing intolerance towards ethnic, religious and sexual minorities in Indonesia, attacks against peacekeepers in Central African Republic and breaches of human rights in Burundi, in three resolutions voted on Thursday.
UK and Gibraltar are a single Member State for the purposes of the freedom to provide services20/01/2017 15:15:00
The Advocate General concludes that the application of EU law to Gibraltar does not create new or supplementary rights between the UK and Gibraltar that are in addition to those flowing from UK and Gibraltar constitutional law.
MEPs reject EC blacklist of states at risk of money laundering20/01/2017 14:25:00
MEPs have voted to return to the EU Commission its blacklist of countries deemed to be at risk of money laundering and terrorist financing. The list is too limited, and should be expanded, e.g. to include territories that facilitate tax crimes, they said before voting the resolution on Thursday.
Refugees: MEPs demand emergency winter aid and transfers to other EU countries20/01/2017 14:15:00
EU and national authorities should provide emergency aid to help migrants & refugees to cope with freezing temperatures & snow in several parts of Europe, MEPs urged on Wednesday. They also called on EU governments to keep their promises to transfer thousands of asylum-seekers, particularly from Greece, to other countries.